MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/svin.125.002111

Медицинская библиотека · Stroke (Hoboken, N.J.) · 2026

Paclitaxel Drug-Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A US Single-Center Experience With the AGENT Balloon.

Chaudhari Amit, Rosenstein Zachary M, Kamal Rashed, Khan Niha, Almajali Mohammad, Ramirez-Abreu Darwin, Al-Ghetaa Jaafar Kashef, Ashouri Yazan, Lin Eugene, Zaidat Osama O

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Intracranial atherosclerotic disease is associated with up to 10% of ischemic strokes and a high risk of recurrence. Endovascular treatments including percutaneous transluminal angioplasty and stenting have failed to demonstrate improved outcomes compared with medical therapy alone. Drug-coated balloon (DCB) angioplasty has emerged as a promising alternative, though its safety and durability remain uncertain.

METHODS

This single-center retrospective study analyzed consecutive patients with refractory intracranial atherosclerotic disease treated with AGENT drug-coated balloon submaximal angioplasty. Stenosis was quantified according to the WASID criteria (Warfarin-Aspirin Symptomatic Intracranial Disease). Patients were treated either for refractory large-vessel occlusion during thrombectomy (emergency rescue) or for recurrent ischemic symptoms from high-grade stenosis (elective primary). Primary outcome was technical success, defined as <50% residual stenosis after DCB angioplasty without the need for adjunctive percutaneous transluminal angioplasty and stenting. Safety outcomes included periprocedural intracranial hemorrhage, vessel dissection, symptomatic reocclusion, ischemic stroke, and mortality at 1 month and 3 months.

RESULTS

Of the 11 identified patients, 9 underwent successful DCB angioplasty, 5 for emergent rescue therapy, and 4 for elective primary therapy. There was a combined technical success rate of 78%, with no major procedural complications. Mean stenosis reduction was 53.6% (paired Wilcoxon P=0.014; preprocedure mean [SD] stenosis 90.8% [±8.6%] to postprocedure 37.3% [±33.4%]). Restenosis occurred in 3 of the 4 (75%) elective primary patients on follow-up imaging at a mean of 64 days postprocedure, without recurrent ischemic events. Follow-up angiographic data for the emergent rescue cohort was unavailable, though no symptomatic ischemic events were reported.

CONCLUSIONS

Paclitaxel-coated AGENT DCB submaximal angioplasty was safe and yielded immediate improvements in luminal diameter. However, high rates of restenosis emphasize the need for innovative devices and larger prospective studies to define its therapeutic role for refractory intracranial atherosclerotic disease.

Для цитирования: Chaudhari Amit, Rosenstein Zachary M, Kamal Rashed, Khan Niha, Almajali Mohammad, Ramirez-Abreu Darwin, Al-Ghetaa Jaafar Kashef, Ashouri Yazan, Lin Eugene, Zaidat Osama O. Paclitaxel Drug-Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A US Single-Center Experience With the AGENT Balloon.. Stroke (Hoboken, N.J.). 2026. DOI: 10.1161/svin.125.002111.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.